Lv4
478 积分 2026-07-04 加入
Experiencing Transitions: An Emerging Middle-Range Theory
15天前
已完结
Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
1个月前
已完结
FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer
1个月前
已完结